KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nektar Therapeutics (NKTR) Change in Receivables: 2009-2024

Historic Change in Receivables for Nektar Therapeutics (NKTR) over the last 16 years, with Dec 2024 value amounting to $3.0 million.

  • Nektar Therapeutics' Change in Receivables rose 320.62% to $2.2 million in Q4 2024 from the same period last year, while for Dec 2024 it was $3.0 million, marking a year-over-year increase of 163.76%. This contributed to the annual value of $3.0 million for FY2024, which is 163.76% up from last year.
  • As of FY2024, Nektar Therapeutics' Change in Receivables stood at $3.0 million, which was up 163.76% from -$4.8 million recorded in FY2023.
  • In the past 5 years, Nektar Therapeutics' Change in Receivables registered a high of $3.0 million during FY2024, and its lowest value of -$16.5 million during FY2022.
  • Moreover, its 3-year median value for Change in Receivables was -$4.8 million (2023), whereas its average is -$6.1 million.
  • Its Change in Receivables has fluctuated over the past 5 years, first plummeted by 548.04% in 2021, then soared by 163.76% in 2024.
  • Over the past 5 years, Nektar Therapeutics' Change in Receivables (Yearly) stood at -$1.9 million in 2020, then plummeted by 548.04% to -$12.4 million in 2021, then plummeted by 33.19% to -$16.5 million in 2022, then spiked by 71.07% to -$4.8 million in 2023, then spiked by 163.76% to $3.0 million in 2024.